Unlocking and delivering the promise of therapeutic nitric oxide
To develop and define new models of care across many serious medical conditions by enhancing the body’s healing and defence mechanisms.
Nitric oxide (NO) is a volatile gas, produced in tissues of the body and acts as a vital cell-to-cell signalling mechanism. The discovery that NO is involved in a number of critical physiological processes led to a 1998 Nobel Prize.
Since then, a number of attempts have been made to harness its multiple therapeutic effects, which include increased blood flow, regulation of immune response, broad-spectrum anti-microbial activity, and acceleration of healing.
However, NO has a very short half-life, and sustained release and practical delivery is very difficult to attain. Further, in air, NO is oxidised to nitrogen dioxide (a useless, toxic gas). 30 Technology has solved these previously intractable problems, utilising proprietary IP to create a platform technology which uniquely creates the opportunity to use NO in a variety of diseases and health conditions.
Additionally, our revolutionary 30Technology™ Intellectual Property allows us to deliver sustained NO via topical patches, gels, liquids and even aerosol delivery platforms.
30Technology™ was created as a group of six wholly owned subsidiaries aligned to its research programmes and market verticals:
30 Respiratory; 30 Woundcare; 30 Therapeutics; 30 Pharma; 30 Dermatology; 30 Animal Health
OUR REVOLUTIONARY TECHNOLOGY IS CLINICALLY PROVEN AND A POTENT SOLUTION TO MANY
SERIOUS MEDICAL CONDITIONS.
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide